课题基金 / 基金详情

Biomarkers of Opisthorchis viverrini-induced cholangiocarcinoma

Biomarkers of Opisthorchis viverrini-induced cholangiocarcinoma
Opisthorchis viverrini 诱导的胆管癌的生物标志物
批准号:
8665533
负责人:
Jeffrey Michael Bethony
金额:
$6.86万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-04-15 至 2016-03-31
关键词:

项目摘要

项目成果

Jeffrey Michael Bethony的其他基金

相似基金

相关文献

中文摘要
翻译
描述(申请人提供):胆管癌(CCA)-胆道癌-与较晚的临床表现有关,对诊断构成挑战,并具有高死亡率,这些特征突显了对生物标记物的需求,这些生物标记物可以在早期和可获得的样本中进行测量,如血浆。然而,尽管进行了广泛的研究,但仍未能产生对CCA具有足够诊断准确性和实用性的生物标记物。我们将通过在全球CCA中心泰国坤健省开展生物标记物计划来解决之前发现CCA生物标记物(S)的限制,泰国是世界上肝内CCA发病率最高的地方。这项提议成功的一个关键因素是,尽管西方CCA的致病因素仍不清楚,但泰国肝内CCA最重要的单一风险因素早已确定-感染肝吸虫。根据世界卫生组织国际癌症研究中心的结论,在人类恶性肿瘤和真核病原体之间没有比CCA和卵子感染之间存在更强的联系。我们将利用寄生虫感染和癌症之间的这种公认的联系来发现和验证血浆中CCA的生物标记物。使用定量蛋白质组学方法,我们建议扫描30个冷冻的、切除的来自OV诱导的CCA病例的肝肿瘤组织,以组装一套位于疾病部位近端的蛋白质(候选生物标记物)。我们将通过扫描CCA细胞系来补充这一分析,与冰冻肝脏切片不同,CCA细胞系测量分泌/膜蛋白(分泌组)的表达。从这两个来源确定的潜在生物标记物将在与确诊的OV诱导CCA患者的30个冷冻、切除的肝组织配对的血浆样本中得到验证。候选生物标记物随后将在我们NIAID赞助的纵向研究的病例对照研究中在OV感染的CCA风险个人的血浆中得到验证,该研究追溯了胆管癌变从慢性Oviverrini感染到CCA的发生。使用这组特殊的样本将使我们能够解决CCA生物标记物发现之前的限制如下。首先,我们可以通过确定OV感染来可靠地衡量暴露的风险。其次,坤健研究地点是世界上CCA发病率最高的地方,使我们能够获得大量的CCA样本。第三,使用我们由NIAID赞助的纵向研究,我们可以沿着整个连续体追踪发病机制:从感染OV到诊断CCA。第四,我们计划在肿瘤近端的银行组织(切除的肝脏)中发现生物标记物,然后在这些CCA患者的血浆中进行验证,然后在我们的队列研究中对“高危”患者进行验证。因此,这一建议的最大创新是我们将利用一个人类致癌模型,在该模型中,主要风险因素以及通往CCA的许多中间阶段都得到了很好的定义。
英文摘要
DESCRIPTION (provided by applicant): Cholangiocarcinoma (CCA) - bile duct cancer - is associated with late presentation, poses challenges for diagnosis and has high mortality, features that highlight the need for biomarkers than can be measured early and in accessible samples such as plasma. However, despite extensive investigations, efforts have failed to yield biomarkers with adequate diagnostic accuracy and utility for CCA. We will address previous limitations in the discovery of CCA biomarker(s) by undertaking a biomarker program in the global epicenter of CCA, Khon Kaen province, Thailand, which has highest incidence of intrahepatic CCA in the world. A key factor in the success of this proposal is that, while the causative agent for CCA in the West remains obscure, the single most important risk factor for intrahepatic CCA in Thailand has long been established - infection with the liver fluke Opisthorchis viverrini (OV). As determined by the WHO's IARC, no stronger link between a human malignancy and a eukaryotic pathogen exists than between CCA and infection with OV. We will utilize this well-established link between a parasite infection and cancer for the discovery and verification of biomarkers for CCA in plasma. Using a quantitative proteomic approach, we propose to scan 30 frozen, resected liver tumor tissues from confirmed OV-induced CCA cases to assemble a suite of proteins (candidate biomarkers) proximal to the disease site. We will complement this analysis with a scan of CCA cell lines which, unlike the frozen liver sections, measure the expression of secreted/membrane proteins (the secretome). Potential biomarkers identified from these two sources will be verified in plasma samples paired with the 30 frozen, resected liver tissues from confirmed OV-induced CCA patients. The candidate biomarkers will then be verified in the plasma of OV- infected individuals at risk for CCA in a case control study from our NIAID-sponsored longitudinal study that traces cholangiocarcinogenesis from chronic O. viverrini infection to CCA. The use of this exceptional set of samples will enable us to address previous limitations to CCA biomarker discovery as follows. First, we can reliably measure risk for exposure by determining infection with OV. Second, the Khon Kaen study site has the highest incidence of CCA in the world, giving us access to large numbers of CCA samples. Third, using our NIAID-sponsored longitudinal study, we can trace pathogenesis along the entire continuum: from infection with OV to diagnosis with CCA. Fourth, we plan biomarker discovery in banked tissue proximal to the tumor (resected liver) followed by verification in plasma from these same CCA patients and then in "at risk" patients in our cohort study. Hence, the overarching innovation of this proposal is that we will utilize a model of human carcinogenesis in which the major risk factor, as well as many of the intermediate stages on the pathway, to CCA have been well-defined.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Controlled Infection Trial to Test Efficacy of Hookworm Vaccine with Different TLR Agonists
  • 批准号:
    10556618
  • 项目类别:
  • 资助金额:
    $48.09万
  • 财政年份:
    2017
  • 负责人:
    Jeffrey Michael Bethony
  • 依托单位:
Controlled Infection Trial to Test Efficacy of Hookworm Vaccine with Different TLR Agonists
  • 批准号:
    9914089
  • 项目类别:
  • 资助金额:
    $73.15万
  • 财政年份:
    2017
  • 负责人:
    Jeffrey Michael Bethony
  • 依托单位:
AIDS and Cancer Specimen Resource (ACSR)
  • 批准号:
    10686329
  • 项目类别:
  • 资助金额:
    $483.11万
  • 财政年份:
    2013
  • 负责人:
    Jeffrey Michael Bethony
  • 依托单位:
AIDS and Cancer Specimen Resource (ACSR)
  • 批准号:
    10477357
  • 项目类别:
  • 资助金额:
    $483.07万
  • 财政年份:
    2013
  • 负责人:
    Jeffrey Michael Bethony
  • 依托单位:
海外基金